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Abstract
Background: Resistance to anti-malarials is a major public health problem worldwide. After deployment of
artemisinin-based combination therapy (ACT) there have been reports of reduced sensitivity to ACT by malaria
parasites in South-East Asia. In Tanzania, artemether-lumefantrine (ALu) is the recommended first-line drug in treatment
of uncomplicated malaria. This study surveyed the distribution of the Plasmodium falciparum multidrug resistance
protein-1 single nucleotide polymorphisms (SNPs) associated with increased parasite tolerance to ALu, in Tanzania.
Methods: A total of 687 Plasmodium falciparum positive dried blood spots on filter paper and rapid diagnostic test
strips collected by finger pricks from patients attending health facilities in six regions of Tanzania mainland between
June 2010 and August 2011 were used. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP)
technique was used to detect Pfmdr1 SNPs N86Y, Y184F and D1246Y.
Results: There were variations in the distribution of Pfmdr1 polymorphisms among regions. Tanga region had
exceptionally high prevalence of mutant alleles, while Mbeya had the highest prevalence of wild type alleles. The
haplotype YFY was exclusively most prevalent in Tanga (29.6%) whereas the NYD haplotype was the most prevalent in
all other regions. Excluding Tanga and Mbeya, four, most common Pfmdr1 haplotypes did not vary between the
remaining four regions (χ2 = 2.3, p = 0.512). The NFD haplotype was the second most prevalent haplotype in all regions,
ranging from 17% - 26%.
Conclusion: This is the first country-wide survey on Pfmdr1 mutations associated with ACT resistance. Distribution of
individual Pfmdr1 mutations at codons 86, 184 and 1246 varies throughout Tanzanian regions. There is a general
homogeneity in distribution of common Pfmdr1 haplotypes reflecting strict implementation of ALu policy in Tanzania
with overall prevalence of NFD haplotype ranging from 17 to 26% among other haplotypes. With continuation of ALu
as first-line drug this haplotype is expected to keep rising, thus there is need for continued pharmacovigilance studies
to monitor any delayed parasite clearance by the drug.
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Background
Plasmodium falciparum multidrug resistance protein-1
(Pfmdr1) is an adenosine triphosphate-binding cassette
protein located on the parasite’s food vacuole [1]. Muta-
tions in the Pfmdr-1 coding gene leading to amino acid
changes in Pfmdr1 have different consequences on para-
site’s sensitivity to anti-malarial drugs. Several Pfmdr1
single nucleotide polymorphisms have been reported
whereby N86Y, Y184F, S1034C, N1042D and D1246Y
are the most common. Pfmdr1 86Y mutation is associ-
ated with chloroquine (CQ) and amodiaquine (AQ) re-
sistance [2-4], while 1034C, 1042D and 1246Y mutations
have been reported to confer resistance against quinine
(QN) and increased susceptibility to mefloquine (MQ),
halofantrine (HF) and artemisinin [5-7]. Furthermore,
the 86Y and 1246Y are highly associated with decreased
sensitivity to artesunate-amodiaquine (AS-AQ), while
the wild types N86 and D1246 are linked to artemether-
lumefantrine (ALu) resistance [8-10]. Recent studies
have shown that the combination of N86, 184 F, and
D1246 forming a haplotype “NFD” lead to decreased
susceptibility to ALu and that treatment with ALu se-
lects for such haplotype [11,12]. Furthermore, an in-
crease of asexual parasites and gametocytes harboring
Pfmdr1 NFD haplotype in patients treated with ALu was
linked with treatment failure [12].
In Tanzania, ALu was adopted as first-line treatment
drug in December 2006 [13]. A recent study in Korogwe,
Tanga region reported increase of N86 from 25% to 59%
and 184 F from 10% to 30% in 2006 to 2010 [14]. An-
other study in Igongwe, Mwanza pointed out an increase
of N86 in samples collected post ALu treatment as com-
pared with pretreatment samples; from 6.3 to 42,1%
[15]. Also in Bagamoyo Pwani region, Malmberg and
colleagues reported increase from 10 to 37% of the NFD
haplotype from 2006 to 2011 [16]. A similar selection of
NFD by ALu was observed in Mozambique [17]. In
Kenya the Y184F was associated with high artemisinin
IC50 levels in ex-vivo drug sensitivity assays while the
wild type N86 was associated with high MQ IC50 [10].
Furthermore, P. falciparum parasites carrying NFD
haplotype were able to withstand 15-fold higher blood
lumefantrine levels than those with YYY (86Y-Y184-
1246Y) haplotype [18]. Recently, ACT resistance associ-
ated K13 propeller protein mutations selected through
increasing drug pressure in laboratory strains and subse-
quently found in field isolates from South-East Asia
were reported [19]. Together with the Pfmdr1 ALu-
associated haplotypes the K13 polymorphism is evidence
of emerging tolerance to ACT and calls for continuous
monitoring surveillance studies. Following five years of
ALu treatment policy implementation in Tanzania there
is scarcity of information on current status of ACT
markers of resistance. Of the studies reported to-date
most were conducted a few years around the official
adoption of ALu in the country (from 2003–2009), while
the few most recent had inadequate sample size or did
not cover the NFD haplotype with exception of one
study [16] conducted in 2010. This study reports on the
current status of the Pfmdr1 NFD haplotype in six re-
gions of Tanzania which can be used as a baseline status
for future studies in predicting the trends and for moni-
toring ALu efficacy.
Methods
Description of study subjects and study sites
Samples used in this study were obtained through col-
laboration with ongoing studies in six regions of main-
land Tanzania between June 2010 and August 2011.
Except for the Coastal region where the samples in-
volved pregnant women attending the Kibiti health
centre for antenatal care, all other samples were col-
lected from all-age groups. Finger prick blood on filter
paper (Whatman-3) or malaria rapid diagnostic test
(RDT) (Paracheck, Orchid Biomedical Systems, India)
(Mwanza samples only) from febrile patients attending
to various health facilities in the respective regions were
collected after patient’s or children’s guardians had con-
sented for use of their blood samples for malarial genetic
studies. The study sites (with their respective number of
samples in brackets) include Mwanza (Misungwi district,
n = 107) and Kagera (Muleba district, n = 129) around
Lake Victoria in the north-western zone, Tanga (Bondo vil-
lage, n = 94) in north-eastern zone, Mtwara (Tandahimba
and Mtwara-Urban, n = 70) and Coastal Region (Kibiti-
Rufiji, n = 144) in south-eastern zone and Mbeya (Kyela
and Rungwe districts, n = 143) in the south-western zone.
DNA extraction and genotyping of the Pfmdr1 gene
Malaria-positive RTDs or dried filter paper blood spots
from microscopically confirmed cases were stored in
desiccants at room temperature. Malaria parasite DNA
was extracted using chelex-100 method as described
previously [20]. Genotyping for Pfmdr1 was performed
using PCR-RFLP-methods described elsewhere [7,21]. In
brief, PCR products were digested with ApoI and Afl-III
which recognize the 86 N and (86Y) respectively, Dra-I
which recognises the 184Y and EcoRV which recognises
1246Y. Endonuclease digest products were eluted on 2.5%
agarose gel (Amasham Biosciences, Sweden) stained with
ethidium bromide (Sigma Aldrich, USA) and visualized
under ultraviolet light. PCR reagents and restriction endo-
nucleases were purchased from New England Biolabs
(NEB inc., Ipswich, MA, USA). Primers were purchased
from Biolegio (Biolegio Inc., The Netherlands). Prevalence
was calculated by adding the number of samples carrying
mixed infections to both wild-type allele and mutant al-
lele, thereby obtaining a new ‘n’ (which includes the mixed
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infections twice). Prevalence of wild-type and mutant al-
lele was then calculated as the percentage of wild-type
plus mixed infection or mutants plus mixed infection out
of the new ‘n’. For the haplotype analysis the mixed infec-
tions were however excluded.
Statistical analysis was performed using Pearson Chi-
squire (SPSS version 16) and Fisher’s exact (FE) test. The
study received ethical approval from the Kilimanjaro
Christian Medical University College ethical board sub-
sequent to the National IRB (NIMR) approval obtained
in the collaborating projects.
Results
Out of the 687 samples, 644 (93.7), 641 (93.3) and 646
(94%) were successfully genotyped for Pfmdr1 N86Y,
Y184F and D1246Y SNPs respectively. There was statis-
tically significant difference in the distribution of indi-
vidual Pfmdr1 polymorphisms among the regions; N86Y
(χ2 = 91.0, p <0.0001), Y184F (χ2 = 68.4, p < 0.0001) and
D1246Y (χ2 = 73.7, p < 0.0001). Tanga region had the
highest prevalence of mutant alleles in all codons while
Mbeya had the highest prevalence of wild type alleles for
N86Y and Y184F (Table 1 and Figure 1).
Haplotype analysis
When the SNPs were constructed into codon 86-184-
1246 haplotypes, eight haplotypes were detected among
578 of the samples, omitting samples that had mixed
genotype infections (Table 2) and those that could not
be genotyped for all the three SNPs. Of these haplotypes,
Table 1 Distribution of Pfmdr1 single nucleotide polymorphisms in Tanzania
Regions Pfmdr1 polymorphisms
N86Y Y184F D1246Y
N Y N/Y Y Y F Y/F F D Y D/Y Y
n (%) n (%) n (%) Prevalence
(%)
n (%) n (%) n (%) Prevalence
(%)
n (%) n (%) n (%) Prevalence
(%)
Tanga 36 (38.3) 56 (59.6) 2 (2.1) 58 (60.4) 32 (34.8) 60 (65.2) 0 (0) 60 (65.2) 45 (52.9) 39 (45.9) 1 (1.2) 40 (46.5)
Coastal 93 (72.1) 33 (25.6) 3 (2.3) 36 (27.3) 85 (63.0) 50 (37.0) 0 (0) 50 (37.0) 134 (93.7) 7 (4.9) 2 (1.4) 9 (6.2)
Mtwara 49 (74.2) 16 (24.2) 1 (1.5) 17 (25.4) 43 (64.2) 23 (34.3) 1 (1.5) 24 (35.3) 55 (78.6) 15 (21.4) 0 (0) 15 (21.4)
Kagera 90 (72.0) 31 (24.8) 4 (3.2) 35 (27.1) 82 (67.8) 38 (31.4) 1 (0.8) 39 (32.6) 112 (88.2) 13 (10.2) 2 (1.6) 15 (11.6)
Mbeya 129 (95.6) 4 (3.0) 2 (1.5) 6 (4.4) 111 (88.0) 13 (10.3) 2 (1.6) 15 (11.7) 119 (89.5) 13 (9.8) 1 (0.8) 14 (10.4)
Mwanza 72 (77.1) 23 (22.9) 0 (0) 23 (24.2) 64 (64.0) 35 (35.0) 1 (1.0) 36 (35.6) 73 (83.0) 15 (17.0) 0 (0) 15 (23.6)
Total 469 (72.8) 163 (25.3) 12 (1.8) 417 (65) 219 (34.2) 5 (0.7) 538 (83) 102 (15.7) 6 (0.9)
Figure 1 Prevalence of the Pfmdr1 N86Y, Y184F, and D1246Y polymorphisms by region in Tanzania. Shown in black, Wild-types; brick-red:
Mutants and Blue: mixed genotypes.
Kavishe et al. Malaria Journal 2014, 13:264 Page 3 of 6
http://www.malariajournal.com/content/13/1/264
the most common were NYD (43.6%), NFD (21.1%) and
YYD (12.3%) haplotypes (Figure 2). A minor haplotype
YFY (4.8%), was almost exclusively present in Tanga re-
gion (85.7% of total YFY haplotypes) compared to other
regions and was the most prevalent (29.6%) of the eight
haplotypes in that region. Conversely, the NYD was the
most prevalent in all other regions, with a markedly high
prevalence in Mbeya (77.5%) compared to the other re-
gions (Figure 2). When comparing individual haplotypes
against the regions, each haplotype varied significantly
between the regions (p < 0.05). However, when Mbeya
with exceptionally high wild-type haplotype (77.5%) was
excluded, the NFD distribution did not vary between the
regions (χ2 = 2.3, p = 0.512). Furthermore, when both
Mbeya and Tanga were excluded from the analysis, all
the common haplotypes did not vary significantly among
the regions (YYD: χ2 = 0.32, p = 0.952; NYD: χ2 = 1.498,
p = 0.683; NFD: χ2 = 0.28, p = 0.964 and YFY: FE = 2.77,
p = 0.462). Mbeya and Tanga regions were, therefore, ex-
ceptional with Tanga having the most mutant alleles at
the three codons while Mbeya had the most wildtypes in
two of the three.
Discussion
Molecular markers are useful predictors of emerging or
existing levels of resistance to anti-malarial drugs. The
surveillance of these markers have proven important
during recent years where reports on the molecular
marker for chloroquine (CQ) resistance; Pfcrt have
shown recovery of CQ sensitivity in Mozambique and
Tanzania [22-24]. Furthermore, accumulation of muta-
tions in the genes Pfdhfr and Pfdhps associated to
sulphadoxine-pyrimethamine (SP) resistance have re-
cently been shown to culminate with the emergence of
Table 2 Prevalence of the Pfmdr1 haplotypes in six regions of Tanzania
Regions Pfmdr1 haplotypes Total (N)
NYD NYY NFY NFD YYY YYD YFD YFY
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Tanga 9 (11.1) 7 (8.6) 2 (2.5) 14 (17.3) 4 (4.9) 8 (9.9) 13 (16.0) 24 (29.6) 81
Coastal 53 (44.9) 2 (1.7) 2 (1.7) 28 (23.7) 1 (0.8) 17 (14.4) 14 (11.9) 1 (0.8) 118
Mtwara 25 (39.7) 5 (7.9) 3 (4.8) 16 (25.4) 2 (3.2) 10 (15.9) 1 (1.6) 1 (1.6) 63
Mbeya 86 (77.5) 10 (9.0) 0 (0.0) 11 (9.9) 1 (0.9) 3 (2.7) 0 (0.0) 0 (0.0) 111
Kagera 46 (41.4) 5 (4.5) 2 (1.8) 29 (26.1) 5 (4.5) 19 (17.1) 5 (4.5) 0 (0.0) 111
Mwanza 33 (36.7) 9 (10.0) 5 (5.6) 24 (26.7) 2 (2.2) 14 (15.6) 1 (1.1) 2 (2.2) 90
Total N (%) 252 (43.6) 38 (6.6) 14 (2.4) 122 (21.1) 15 (2.6) 71 (12.3) 34 (5.9) 28 (4.8) 578
Figure 2 Prevalence of Pfmdr1 N86Y, Y184F, and D1246Y haplotypes in Tanzania. The number of samples analyzed per region were Tanga
(n = 81), Coastal (n = 118), Mtwara (n = 70), Mbeya (n = 111), Mwanza (n = 90) and Kagera (n = 111).
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sextuple Pfdhfr and Pfdhps mutants [25,26]. These super-
resistant mutants render intermittent preventive treat-
ment of pregnant women (IPTp) using SP redundant in
places such as in Tanga where high prevalence of such
mutants have been documented [27]. In this study, vari-
ation in the distribution of Pfmdr1 polymorphisms among
regions in Tanzania is reported. The overall prevalence of
single SNPs and as well, the resulting triple 86-184-1246
haplotype YFY haplotype was highest in Tanga. Interest-
ingly, this coincides with highest prevalence of SP resist-
ance markers also documented in Tanga region [25,28,29].
The haplotype YFY is linked to AQ and CQ resistance
[21]. On the other hand high prevalence of NYD haplo-
type was highest in Mbeya region. This made Tanga and
Mbeya regions different from the rest of the studied re-
gions. While there is no clear explanation for Mbeya, a
general very high malaria transmission thus high use of
anti-malarials especially in early 1980s and 1990s may
have led to a particularly high selection pressure for resist-
ant parasites in Tanga relative to other places in Tanzania
[30,31]. In a recent survey on availability of anti-malarials
in Muheza Tanga, AQ and SP were still available in private
shops and used by the local population for malaria self-
medication [32]. Continued use of AQ in the study area or
neighbourhood may account for the observed high YFY
haplotype. Also these findings point to a possible low ad-
herence to the ALu treatment policy in Tanga relative to
other regions.
The NFD did not vary between five of the regions.
These results show homogeneity in Pfmdr1 haplotypes
distribution, which suggests similar selection pressure
throughout the country, indicative of homogeneity in ALu
policy implementation in Tanzania. ALu has been shown
to select for the NFD haplotype, where the prevalence of
86Y and 1246Y mutations has been decreasing while the
184 F has been increasing [11,14,17]. In this study, low
prevalence of mutations 86Y and 1246Y were observed
relative to 184 F. Similar findings elsewhere in East and
West Africa have been reported where ALu is the treat-
ment policy [33-35]. In recent in-vitro studies done using
parasite isolates in Senegal and South East Asia, the 86Y
and 1246Y were associated with high CQ, AQ and MQ in-
hibitory concentrations (IC50) whereas the 184 F was
associated with high artemisinin IC50 values [36,37]. Fur-
thermore, in Cambodian samples the prevalence of the
184 F mutation selectively increased after ACT pressure
[38]. These reports are suggestive of some overlap in
mechanism of ACT resistance between South-East Asia
and Africa and that these molecular markers can serve as
universal tools for ACT resistance monitoring.
Conclusions
This is the first country-wide survey on Pfmdr1 muta-
tions associated with ACT resistance. Distribution of
Pfmdr1 mutations at codons 86, 184 and 1246 varies
throughout Tanzanian regions. There is homogeneity in
distribution of common Pfmdr1 haplotypes in four out
of six regions of Tanzania which may reflects homogen-
eity in countrywide implementation of ALu policy. The
overall prevalence of NFD haplotype claimed to be asso-
ciated with emerging ALu tolerance ranges from 17 to
26% among other haplotypes. With continuation of ALu
as first-line drug and in the absence of CQ and AQ, this
haplotype is expected to keep rising. There is need for
continued pharmacovigilance studies in order to predict
early parasite tolerance to the drug.
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